Opendata, web and dolomites


Personalised Pancreatic Cancer Vaccination Therapy derived from Autologous Tumor Cells and Neoantigens

Total Cost €


EC-Contrib. €






Project "PanCaVax" data sheet

The following table provides information about the project.


Organization address
address: OXFORDLAAN 55
postcode: 6229 EV
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYTUVAX BV NL (MAASTRICHT) coordinator 50˙000.00


 Project objective

CyTuVax B.V. is a biotech enterprise founded in Maastricht (the Netherlands) in October 2012. It applies depot-formulated cytokines (interaction molecules of the immune system), which enhance immune responses in an unprecedented manner when used in extremely high local density. Single and multi-cytokine combinations can be formulated by simple procedures and act as strong adjuvants, driving immune responses to their limits. It is a universal, patented platform adjuvant technology that can be applied to any vaccines and can have great influence on future vaccine technology. CyTuVax achieved the first clinical proof of concept in a Phase I trial in which 90% of hepatitis B non-responders were successfully vaccinated. Phase II is on-going. CyTuVax decided now to focus on the challenging problem of developing a vaccine for pancreatic cancer, a deadly disease for which no curative treatment exists. Its cancer vaccination therapy (PanCaVax) should substantially improve the life-expectancy by extending the median survival rate to at least 12-24 months. Costs of PanCaVax will be considerably less compared to checkpoint inhibitor antibodies, with locally strong, but systemically mild, side effects expected. CyTuVax’ highly motivated team’s next step is to complete the preclinical development of PanCaVax. Key impact of our innovation would be that it is providing a favorable clinical outcome and sufficient proof of efficacy to obtain financial resources for next steps in Phase IIb/IIIa, regulatory approval and ultimate access to pancreatic cancer patients currently lacking an acceptable therapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PANCAVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PANCAVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More